Randomised phase II study of Gemcitabine (Gem) or Methotrexate and Vinblastine (Mv) in advanced transitional cell carcinoma of the urothelium.

Trial Profile

Randomised phase II study of Gemcitabine (Gem) or Methotrexate and Vinblastine (Mv) in advanced transitional cell carcinoma of the urothelium.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Methotrexate; Vinblastine
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top